Article Text

Download PDFPDF
Management of HBV- and HCV-induced end stage liver disease
  1. David J Mutimer1,2,
  2. Anna Lok3
  1. 1Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Birmingham, UK
  2. 2NIHR Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, UK
  3. 3Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, Michigan, USA
  1. Correspondence to Dr David J Mutimer, Liver and Hepatobiliary Unit, Queen Elizabeth Hospital, Third Floor Nuffield House, Birmingham B15 2TH, UK; david.mutimer{at}


Hepatitis B and hepatitis C infections are important causes of end-stage liver disease and primary liver cancer. Successful antiviral treatment prior to the development of cirrhosis will prevent most of the morbidity and mortality associated with those infections. This can be achieved for a high proportion of patients. However, many patients present with end-stage liver disease and ongoing and clinically significant viral replication. Antiviral treatment of HBV can effect recovery of liver function and restores many patients to a state of well compensated cirrhosis. The antiviral treatment of end-stage HCV poses much greater challenges. Interferon remains an essential element of HCV antiviral treatment, but has reduced efficacy and significant toxicity at this stage of cirrhosis. Though yet to be evaluated in the setting of advanced liver disease, the development of direct acting antivirals for HCV offers hope for improved outcomes at this stage of cirrhosis.

  • Hepatitis B virus
  • hepatitis C virus
  • cirrhosis
  • liver transplantation
  • antiviral therapy

Statistics from


  • Declarations: David Mutimer is and has been a member of advisory boards to Gilead, BMS, Roche, MSD and Janssen pharmaceuticals and has received speaker's honoraria from these companies. Anna Lok is and has been a member of advisory boards/data and safety monitoring panels of Gilead, BMS, Roche, GSK and Abbott, and has received research grants from Gilead, BMS, Merck, Roche and GSK.

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.